IL1B and neoplasm: These results suggest that the NLRP3/IL-1β pathway promotes the development of HNSCC and that modulating of the tumor microenvironment by targeting the NLRP3/IL-1β pathway is expected to be a new therapeutic approach for HNSCC (76).